← К результатам

A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine.

Huang W, Zeng ZC, Wang WT, Sun YM, Chen YQ, Luo XQ, Fang K

Clinical and translational medicine, 11(3): e355 PMID 33783997 DOI 10.1002/ctm2.355